NASDAQ · Biotechnology

Evaxion Biotech A/S (EVAX) Stock

$3.05 +0.66% NASDAQ: EVAX Healthcare

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases.

Valuation

MetricValue
Price$3.05
Market Cap$19.27M
P/E Ratio-1.99
P/B Ratio1.93
P/S Ratio2.56
EPS (TTM)$-1.21
52-Week High$12.15
52-Week Low$2.45
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-73.56%
ROA-41.28%
ROCE-38.87%
Gross Margin100.00%
Operating Margin-122.05%
Net Margin-129.63%
Debt/Equity0.47
Current Ratio6.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$3.0M$8.0M
Operating Profit$-26.0M$-25.0M$-22.0M$-15.0M$-9.0M
Net Profit$-25.0M$-23.0M$-22.0M$-11.0M$-8.0M
EPS$-50.40$-39.20$-32.40$-9.80$-1.21
Op Margin——-30406.8%-440.6%-122.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$40.0M$22.0M$13.0M$12.0M$28.0M
Total Liabilities$8.0M$14.0M$18.0M$14.0M$11.0M
Cash$32.0M$13.0M$6.0M$5.0M$23.0M
Borrowings$4.0M$10.0M$11.0M$10.0M$8.0M

Latest News

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 GlobeNewswire · Jul 12, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT Newswires · Jul 6, 2026 European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading MT Newswires · Jul 2, 2026 European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading MT Newswires · Jul 1, 2026 Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop GlobeNewswire · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-22.0M$-26.0M$-18.0M$-13.0M$-7.0M
Investing Cash Flow$-3.0M$-1.0M$0$0$0
Financing Cash Flow$-4.0M$0$2.0M$-2.0M$0
Net Cash Flow$26.0M$-19.0M$-8.0M$0$17.0M
Free Cash Flow$-23.0M$-26.0M$-18.0M$-13.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.08
FCF Yield0.00%
Quick Ratio6.25
Interest Coverage-11.33
Return 1Y20.08%
Return 3Y-95.16%
Return 5Y-98.91%

Ownership

Insiders Held17.47%
Institutions Held9.40%
Institutions Float Held11.39%
Institutional HolderSharesReport Date
Merck & Co., Inc.1,214,1262026-03-31
Ikarian Capital, LLC74,6982026-03-31
Rathbones Group PLC45,7232026-03-31
Renaissance Technologies, LLC39,2252026-03-31
Annis Gardner Whiting Capital Advisors, LLC 30,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.70 +0.59% -1.54 $33.45M 0.00%
BCABBioAtla, Inc. $3.40 +0.89% -0.08 $4.29M 0.00%
BTAIBioXcel Therapeutics, Inc. $0.87 +2.30% -0.13 $26.77M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%

About Evaxion Biotech A/S

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

Evaxion Biotech A/S is headquartered in DK.

Evaxion Biotech A/S (EVAX) stock trades at $3.05 with a market capitalization of $19.27M. The stock is valued at a price-to-earnings (P/E) ratio of -1.99, price-to-book of 1.93, price-to-sales of 2.56. Over the past 52 weeks the stock has ranged between $2.45 and $12.15, and currently trades 74.9% below its 52-week high.

On profitability, Evaxion Biotech A/S generates a return on equity (ROE) of -73.56%, return on capital employed of -38.87%, an operating margin of -122.05%, a net profit margin of -129.63%.

Official website: www.evaxion-biotech.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides